Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation

Authors


Correspondence

Dr Flora Tshinanu Musuamba, Louvain Drug Research Institute, Avenue Mounier 73, B. 7313 1200 Brussels, Belgium.

Tel.: +0032 (0) 2764 9470

Fax: +0032 (0) 2764 7359

E-mail: flora.musuamba@uclouvain.be

Abstract

Aim

To predict simultaneously the area under the concentration−time curve during one dosing interval [AUC(0,12 h)] for mycophenolic acid (MPA) and tacrolimus (TAC), when concomitantly used during the first month after transplantation, based on common blood samples.

Methods

Data were from two different sources, real patient pharmacokinetic (PK) profiles from 65 renal transplant recipients and 9000 PK profiles simulated from previously published models on MPA or TAC in the first month after transplantation. Multiple linear regression (MLR) and Bayesian estimation using optimal samples were performed to predict MPA and TAC AUC(0,12 h) based on two concentrations.

Results

The following models were retained: AUC(0,12 h) = 16.5 + 4.9 × C1.5 + 6.7 × C3.5 (r2 = 0.82, rRMSE = 9%, with simulations and r2 = 0.66, rRMSE = 24%, with observed data) and AUC(0,12 h) = 24.3 + 5.9 × C1.5 + 12.2 × C3.5 (r2 = 0.94, rRMSE = 12.3%, with simulations r2 = 0.74, rRMSE = 15%, with observed data) for MPA and TAC, respectively. In addition, Bayesian estimators were developed including parameter values from final models and values of concentrations at 1.5 and 3.5 h after dose. Good agreement was found between predicted and reference AUC(0,12 h) values: r2 = 0.90, rRMSE = 13% and r2 = 0.97, rRMSE = 5% with simulations for MPA and TAC, respectively and r2 = 0.75, rRMSE = 11% and r2 = 0.83, rRMSE = 7% with observed data for MPA and TAC, respectively.

Conclusion

Statistical tools were developed for simultaneous MPA and TAC therapeutic drug monitoring. They can be incorporated in computer programs for patient dose individualization.

Ancillary